ScripFour Chinese drug developers have snagged domestic approvals for first-in-class therapies, following on from a similar feat by two of their compatriot companies earlier this year. On July 2, BeBette
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. JCR Adds $825m Gene Therapy Tech D
ScripCargo Therapeutics has managed to find a buyer after announcing in January that it would discontinue the Phase II study of its CD22-targeting CAR-T cell therapy firicabtagene autoleucel (firi-cel) due
ScripThe recent removal of the Risk Evaluation and Mitigation Strategies (REMS) requirement for approved cellular CAR-T therapies for cancer was lauded as an expansion of the market from the two-in-10 el